Ryan J W, Chung A, Ryan U S
Environ Health Perspect. 1980 Apr;35:165-70. doi: 10.1289/ehp.8035165.
The disposition of converting enzyme (kininase II) on the luminal surface of pulmonary endothelial cells is well established. Further, it is known that there is a net conversion of angiotensin I into angiotensin II as blood passes through the lungs. However, little is known about modulations of converting enzyme activity that may arise through, e.g., changes in the quality of inhalants, blood flow, or blood oxygenation. There are few data on the effects of lung disease. A major barrier to studies to examine for pathophysiologic modulations of converting enzyme is that of assay. The enzyme can be measured in terms of the rate of formation of angiotensin II from a known quantity of angiotensin I. However, both peptides are biologically active, and lungs contain other enzymes capable of degrading them. We have developed a series of radiolabeled, acylated tripeptides to improve our ability to examine for changes in the net converting enzyme of intact lungs. The enzyme, a dipeptidyl carboxypeptidase, is capable of removing C-terminal dipeptides from a variety of oligopeptides. We have prepared benzoyl-Gly-Gly-Gly (I), benzoyl-Pro-Phe-Arg (II), benzoyl-Gly-His-Leu (III), benzoyl-Phe-Ala-Pro (IV), and benzoyl-Phe-His-Leu (V), each containing a (3)H-atom in the para position of the benzoyl moiety. Substrates I and III have been used previously in photometric assays of low sensitivity. II is the acylated C-terminal tripeptide of bradykinin, IV is an acylated tripeptide analog of BPP(5a) (<Glu-Lys-Trp-Ala-Pro) and V is the acylated C-terminal tripeptide of angiotensin I. These substrates can be used in vitro or in vivo to measure converting enzyme. The (3)H-labeled product is separable by partitioning between an organic solvent and acidified aqueous solution. The product is quantified by scintillation counting of the organic phase. The choice of substrate depends on the goals of the experiment: substrate I or III when wide variations in substrate concentrations are needed but high sensitivity is not; substrate IV when high sensitivity is needed.
转化酶(激肽酶II)在肺内皮细胞腔面的分布已得到充分证实。此外,已知当血液流经肺部时,血管紧张素I会净转化为血管紧张素II。然而,对于可能因吸入物质量、血流或血液氧合变化等引起的转化酶活性调节知之甚少。关于肺部疾病影响的数据也很少。研究转化酶病理生理调节的一个主要障碍是检测方法。该酶可以根据已知量的血管紧张素I形成血管紧张素II的速率来测量。然而,这两种肽都具有生物活性,并且肺中含有其他能够降解它们的酶。我们开发了一系列放射性标记的酰化三肽,以提高我们检测完整肺脏中净转化酶变化的能力。该酶是一种二肽基羧肽酶,能够从多种寡肽中去除C末端二肽。我们制备了苯甲酰基 - 甘氨酰 - 甘氨酰 - 甘氨酸(I)、苯甲酰基 - 脯氨酰 - 苯丙氨酰 - 精氨酸(II)、苯甲酰基 - 甘氨酰 - 组氨酰 - 亮氨酸(III)、苯甲酰基 - 苯丙氨酰 - 丙氨酰 - 脯氨酸(IV)和苯甲酰基 - 苯丙氨酰 - 组氨酰 - 亮氨酸(V),每种在苯甲酰基部分的对位都含有一个(3)H原子。底物I和III以前曾用于低灵敏度的光度测定。II是缓激肽的酰化C末端三肽,IV是BPP(5a)(<Glu-Lys-Trp-Ala-Pro)的酰化三肽类似物,V是血管紧张素I的酰化C末端三肽。这些底物可用于体外或体内测量转化酶。(3)H标记的产物可通过在有机溶剂和酸化水溶液之间分配来分离。产物通过有机相的闪烁计数进行定量。底物的选择取决于实验目的:当需要底物浓度有很大变化但不需要高灵敏度时选择底物I或III;当需要高灵敏度时选择底物IV。